Inhaled Steroid Growth Effect Label Should Reflect Product Data - Schering
Executive Summary
Inhaled and intranasal corticosteroid products that have demonstrated no effect on pediatric growth should be exempt from FDA's new class labeling for the asthma and allergy drugs, Schering-Plough maintained.
You may also be interested in...
Muro/Adams Tri-Nasal Launch Planned For Fall Allergy Season With 250 Reps
Muro Pharmaceuticals is increasing production to launch its Tri-Nasal intranasal steroid medication by the start of the fall allergy season.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011